Aethlon MedicalAEMD +1.87%23 3-Year RORE % is -64.01 as of Mar. 2026. GuruFocus rates AEMD with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 777 Medical Devices & Instruments companies, Aethlon Medical ranks worse than 86.1% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Aethlon Medical's 3-Year RORE % for the quarter that ended in Mar. 2026 was -64.01%.
The industry rank for Aethlon Medical's 3-Year RORE % or its related term are showing as below:
AEMD's 3-Year RORE % is ranked worse than 86.1% of 777
companies
in the Medical Devices & Instruments industry
Industry Median: -4.03
vs AEMD: -64.01
Aethlon Medical (NAS:AEMD) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Aethlon Medical 3-Year RORE % Related Terms
Aethlon Medical 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Aethlon Medical's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AEMD vs VYCO, RBOT, ESMC: 3-Year RORE % Comparison
For the Medical Devices subindustry, Aethlon Medical's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aethlon Medical 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aethlon Medical's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Aethlon Medical's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Aethlon Medical (AEMD) has a 3-Year RORE % of -64.01 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Aethlon Medical and its competitors. According to the industry distribution chart, Aethlon Medical ranks #669 out of 777 companies in the Medical Devices & Instruments industry, placing it in the top 86.1%.
Is Aethlon Medical's 3-Year RORE % too high?
Aethlon Medical's current 3-Year RORE % is -64.01. Based on the distribution chart, Aethlon Medical ranks #669 out of 777 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Aethlon Medical has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Aethlon Medical's 3-Year RORE % compare to VYCO and RBOT?
According to the Medical Devices & Instruments industry distribution chart, Aethlon Medical ranks #669 out of 777 companies for 3-Year RORE %. This places Aethlon Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Aethlon Medical and its competitors. Aethlon Medical's current 3-Year RORE % is -64.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aethlon Medical stock overvalued right now?
Aethlon Medical (AEMD) has a current 3-Year RORE % of -64.01. The current 3-Year RORE % is -64.01. Aethlon Medical's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Aethlon Medical (AEMD), the current 3-Year RORE % is -64.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.
23GF Score
Get the complete analysis for AEMD
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AEMD has been successfully added to your 
